

Study of efficacy of vitamin D supplement on disease progression and glycemic control in patients with pre-diabetes and type 2 diabetes

Thesis

*Submitted for Partial Fulfillment Of Doctorate degree
in Internal Medicine*

By

Rasha Ahmed Ibrahim

Master degree in Internal Medicine, Ain Shams University

Supervisors

Prof. Dr. Mohammed Hesham El Gayar

*Professor of Internal Medicine & Endocrinology
Ain Shams University*

Prof. Dr. Magda Shukry

*Professor of Internal Medicine & Endocrinology
Ain Shams University*

Prof. Dr. Manal Abu Shady

*Professor of Internal Medicine & Endocrinology
Ain Shams University*

Assist. Prof. Dr. Yara Mohammed Eid

Assistant Professor of Internal Medicine & Endocrinology

Prof. Dr. Safa Refaat

*Professor of Internal Medicine
Research Institute of Ophthalmology*

Faculty of Medicine

Ain Shams University

٢٠١٦



(قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْحَكِيمُ)

صدق الله العظيم

سورة البقرة الآية (٣٢)

Acknowledgement

*First and for most, thanks are due to **ALLAH**, the most beneficent and merciful.*

*I would like to express my sincerest gratitude to **Prof., Dr. Mohammed Hesham El Gayar**, Professor of internal medicine & endocrinology - Ain Shams University. This work has been the fruitful outcome of his valuable advice, super-vision and care.*

*It gives me great pleasure to express my sincere appreciation to **Prof. Dr. Magda Shukry**, Professor of internal medicine & endocrinology - Ain Shams University for her time, insight, and constant support and encouragement*

*I also wish to express my deep sense of gratitude and sincere thanks to **Prof. Dr. Manal Abu Shady**, Assistant Professor of Internal medicine & endocrinology - Ain Shams university, for her continuous super-vision, encouragement and support.*

*I also wish to express my sincere gratitude and thanks to Assist. **Prof. Dr. Yara Eid**, Assistant Professor of Internal medicine & endocrinology - Ain Shams university, for her continuous super-vision, guidance, encouragement and support.*

*I would also like to express my gratitude to **Prof. Dr. Safa Refaat**, Professor of internal medicine - Research Institute of Ophthalmology, for his guidance and support which has been essential to complete this work,*

I feel greatly indebted to Staff members of chemistry lab., Ain shams University hospitals for their serious efforts and valuable suggestions.

It is a great honor to acknowledge my indebtedness to my husband for his great support and encouragement, to my mother and my daughter.

Contents

	<i>Page</i>
١) <i>Introduction</i>	١
٢) <i>Aim of work</i>	٣
٣) <i>Review of literature:</i>	
<i>Chapter (١): Pre-diabetes, type ٢ diabetes mellitus</i>	٤
<i>Chapter (٢): Vitamin D</i>	٥٢
<i>Chapter (٣): Vitamin D and type ٢ diabetes mellitus</i>	١٠٨
٤) <i>Subjects and Methods</i>	١٢٩
٥) <i>Results</i>	١٤٣
٦) <i>Discussion</i>	٢٠٠
٧) <i>Summary and Conclusion</i>	٢١١
٨) <i>Recommendations</i>	٢١٥
٩) <i>References</i>	٢١٦
١٠) <i>Master Sheet</i>	٢٦٩
١١) <i>Arabic summary</i>	٢٩٧

List of Abbreviations

ADAThe American Diabetes Association
AGEsAdvanced glycation end products
BCEBefore the Common Era
BMIBody mass index
CACCoronary artery calcium
CDCCenters for Disease Control and Prevention
CRPC-reactive protein
CTACoronary CT angiography
CVDCardiovascular disease
DBPVitamin D Binding Protein
DCCTDiabetes Control and Complications Trial
DPPDiabetes Prevention Program
DPPOSDiabetes Prevention Program Outcomes Study
DPSDiabetes Prevention Study
FGF-$\gamma\gamma$Fibroblast growth factor $\gamma\gamma$
GDMGestational diabetes mellitus
GFRGlomerular filtration rate
GIGlycemic index
GIPRGastric inhibitory polypeptide
IDFInternational Diabetes Federation

IFGImpaired fasting glucose
IGTImpaired glucose tolerance
MUFAMonounsaturated fatty acids
NGSPNational Glycohemoglobin Standardization Program
NHANES √...National Health and Nutrition Examination Survey Mortality Study
NNSsNon-nutritive sweeteners
OGTTOral glucose tolerance test
PTHParathyroid hormone
SGLT[√]-ISodium-glucose cotransporter-√ inhibitors
SNPsSingle-nucleotide polymorphisms
TNF- αTumour necrosis factor-alpha
UKPDSU.K. Prospective Diabetes Study
Solar Solar Ultraviolet B
VDR.....Vitamin D Receptor
Vitamin D[√] ..Ergocalciferol
Vitamin D[√] ..Cholecalciferol
WHOWorld Health Organization
FPI Fasting plasma insulin
TG Triglycerides
HDL High density lipoprotein
LDL Low density lipoprotein

BMI body mass index

SBP Systolic blood pressure

DBP Diastolic blood pressure

MBP Mean blood pressure

List of Figures

<i>Figure No.</i>	<i>Page No.</i>
Figure (1): Top countries for people with diabetes (20-79 years)	20
Figure (2): Deaths attributable to diabetes by age (20-79)..	21
Figure (3): Abbreviated algorism of anti-hyperglycemic therapy of type 2 diabetes	22
Figure (4): Chemical structure of vitamin D	23
Figure (5): Structure of vitamin D ³ (cholecalciferol) and vitamin D ² (ergocalciferol) and their precursors	25
Figure (6): The synthesis and metabolism of vitamin D in the regulation of mineral homeostasis and non-skeletal functions	26
Figure (7): Mechanism of action of vitamin D.....	27
Figure (8): Vitamin D modulates the inflammatory response of immune cells, such as macrophages and monocytes	28
Figure (9): Prevalence of low vitamin D status in various populations	29

Figure (١٠): Major Causes of vitamin D deficiency and potential health consequences	٩٩
Figure (١١): Effect of Vitamin D on gene expression	١١٣
Figure (١٢): Obesity and vitamin D deficiency.....	١٢٢
Figure (١٣): Change in the FBG level in patients receiving or not receiving cholecalciferol in the three studied groups	١٥٢
Figure (١٤): Change in the PPBG level in patients receiving or not receiving cholecalciferol in the three studied groups	١٥٣
Figure (١٥): Change in the HbA ^١ c level in patients receiving or not receiving cholecalciferol in the three studied groups	١٥٤
Figure (١٦): Change in the FPI level in patients receiving or not receiving cholecalciferol in the three studied groups	١٥٩
Figure (١٧): Percentage of change in the HOMA-IR in patients receiving or not receiving cholecalciferol in the three studied groups	١٦٠
Figure (١٨): Percentage of change in the total serum cholesterol level in patients receiving or not	

receiving cholecalciferol in the three studied groups ١٦٨

Figure (١٩): Percentage of change in the serum TG level in patients receiving or not receiving cholecalciferol in the three studied groups ١٦٩

Figure (٢٠): Percentage of change in the serum HDL level in patients receiving or not receiving cholecalciferol in the three studied groups ١٧٠

Figure (٢١): Percentage of change in the serum LDL level in patients receiving or not receiving cholecalciferol in the three studied groups ١٧١

Figure (٢٢): Percentage of change in the BMI in patients receiving or not receiving cholecalciferol in the three studied groups ١٧٩

Figure (٢٣): Percentage of change in the SBP in patients receiving or not receiving cholecalciferol in the three studied groups ١٨٠

Figure (٢٤): Percentage of change in the DBP in patients receiving or not receiving cholecalciferol in the three studied groups ١٨١

Figure (٢٥): Percentage of change in the MBP in patients receiving or not receiving cholecalciferol in the three studied groups	١٨٢
Figure (٢٦): Correlation between ٢٥ hydroxy-cholecalciferole and age in Pre-diabetics	١٩٠
Figure (٢٧): Correlation between ٢٥ hydroxy-cholecalciferole and age in Pre-diabetics	١٩٠
Figure (٢٨): Correlation between ٢٥ hydroxy-cholecalciferole and HDL in Pre-diabetics	١٩١
Figure (٢٩): Correlation between ٢٥ hydroxy-cholecalciferole and LDL in Pre-diabetics	١٩١
Figure (٣٠): Correlation between ٢٥ hydroxy-cholecalciferole and systolic blood pressure in Naive type ٢ diabetics	١٩٢
Figure (٣١): Correlation between ٢٥ hydroxy-cholecalciferole and height in Naive type ٢ diabetics	١٩٢
Figure (٣٢): Correlation between ٢٥ hydroxy-cholecalciferole and BMI in Naive type ٢ diabetics	١٩٣
Figure (٣٣): Correlation between ٢٥ hydroxy-cholecalciferole and waist circumference in Naive type ٢ diabetics	١٩٣

Figure (٣٤): Correlation between ٢٥ hydroxy-cholecalciferole and cholesterol in Naive type ٢ diabetics ١٩٤

Figure (٣٥): Correlation between ٢٥ hydroxy-cholecalciferole and HDL in Naive type ٢ diabetics ١٩٤

Figure (٣٦): Correlation between ٢٥ hydroxy-cholecalciferole and LDL in Naive type ٢ diabetics ١٩٥

Figure (٣٧): Correlation between ٢٥ hydroxy-cholecalciferole and HDL in treated type ٢ DM ١٩٥

Figure (٣٨): Correlation between ٢٥ hydroxy-cholecalciferole and height in treated type ٢ DM ١٩٦

List of Tables

<i>Table No.</i>	<i>Page No.</i>
Table (١): Recommended targets for glycemic control	٥١
Table (٢): Classification of vitamin D group of molecules ٥٤	
Table (٣): Risk factors for vitamin D insufficiency and deficiency	٩٧
Table (٤): Laboratory and Radiographic findings that suggest possible vitamin D deficiency	٩٨
Table (٥): Vitamin D intakes recommended by the IOM and the Endocrine Practice Guidelines Committee ٢٠١١	١٠٣, ١٠٤
Table (٦): Studies that associate vitamin D with type ٢ diabetes	١١٠
Table (٧): Shows Comparison of Patients' Demographic data	١٤٤
Table (٨): Comparison of anthropometric measurements and biochemical laboratory data	١٤٥
Table (٩): Comparison of the percentage of change in FBG among studied groups by two way ANOVA ...	١٤٧

Table (١٠): Comparison of the percentage of change in FBG among studied groups ١٤٨

Table (١١): Comparison of the percentage of FBG among sub-groups who received cholecalciferol in studied groups ١٤٨

Table (١٢): Comparison of the percentage of change in PPBG among studied groups by two way ANOVA ١٤٩

Table (١٣): Comparison of the percentage of change in PPBG among studied groups ١٤٩

Table (١٤): Comparison of the percentage of PPBG among groups who received cholecalciferol in studied groups ١٥٠

Table (١٥): Comparison of the percentage of change in HbA^{1c} level among studied groups by two way ANOVA ١٥٠

Table (١٦): Comparison of the percentage of change in HbA^{1c} among studied groups ١٥١

Table (١٧): Comparison of percentage of change in Hb^{1Ac} among groups received cholecalciferol in studied groups ١٥١

Table (١٨): Comparison of the percentage of change in Fasting plasma insulin among studied groups by two way ANOVA	١٥٢
Table (١٩): Comparison of the percentage of change in fasting plasma insulin among studied groups ...	١٥٢
Table (٢٠): Comparison of the percentage of change in fasting plasma insulin among those who received cholecalciferol between each ٢ groups	١٥٧
Table (٢١): Comparison of the percentage of change in the HOMA-IR among studied groups by two way ANOVA	١٥٧
Table (٢٢): Comparison of the percentage of change in HOMA-IR among studied groups	١٥٨
Table (٢٣): Comparison of the percentage of change in HOMA-IR among those who received cholecalciferol between each ٢ groups	١٥٨
Table (٢٤): Comparison of the percentage of change in total serum cholesterol level among studied groups by two way ANOVA	١٦٢
Table (٢٥): Comparison of the percentage of change in total cholesterol level among studied groups	١٦٢